Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Considerations in the Development of a Predictive System for Cancer Chemotherapy

William H. Wolberg, MD
Arch Surg. 1971;102(4):344-347. doi:10.1001/archsurg.1971.01350040106021.
Text Size: A A A
Published online


Experience with human responses to antitumor drugs and with cultures of 5-fluoro-2′-deoxyuridine sensitive N1S1 tumor cells exposed to the drug has demonstrated that several factors which are not evaluated in predictive tests may affect the clinical response of tumors to drugs. Such factors lead to discrepancies between the in vitro assessment of response and that actually obtained in the patient. Studies with the fluorinated pyrimidines indicate that the cells must be biochemically sensitive before response can occur. However, biochemical sensitivity may exist and yet no tumor regression occur when the drug is given to the patient. Tumor cells may be killed but their destruction may be masked in at least two ways: Killed, sensitive cells may be replaced by fibrous tissue. Or, drug-resistant cells present in the original tumor may rapidly assume dominance when the sensitive cells are killed. In either case, significant tumor response to drug may escape detection.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.